Title: | Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study |
---|
Authors: | ID Hochmair, Maximilian J (Author) ID Morabito, Alessandro (Author) ID Hao, Desiree (Author) ID Yang, Cheng-Ta (Author) ID Soo, Ross A (Author) ID Yang, James C-H (Author) ID Gucalp, Rasim (Author) ID Halmos, Balazs (Author) ID Wang, Lara (Author) ID Golembesky, Amanda (Author) ID Märten, Angela (Author) ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author) |
Files: | PDF - Presentation file, download (2,39 MB) MD5: 3F2D8BA9D4F2488B02256DB856ABFA69
URL - Source URL, visit https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0711?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed#
|
---|
Language: | English |
---|
Typology: | 1.01 - Original Scientific Article |
---|
Organization: | UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
|
---|
Abstract: | Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. |
---|
Keywords: | lung neoplasms -- therapy, non-small-cell lung cancer, afatinib, osimertinib, epidermal growth factor receptor, EGFR, observational study |
---|
Publication status: | Published |
---|
Publication version: | Version of Record |
---|
Place of publishing: | Velika Britanija |
---|
Publisher: | Future Medicine Ltd |
---|
Year of publishing: | 2018 |
---|
Number of pages: | str. 2861-2874 |
---|
Numbering: | Vol. 14, no. 27 |
---|
PID: | 20.500.12556/DiRROS-12623 ![Link is opened in a new window New window](teme/dirros/img/NovoOkno.png) |
---|
UDC: | 616-006 |
---|
ISSN on article: | 1744-8301 |
---|
DOI: | 10.2217/fon-2018-0711 ![Link is opened in a new window New window](teme/dirros/img/NovoOkno.png) |
---|
COBISS.SI-ID: | 2048432753 ![Link is opened in a new window New window](teme/dirros/img/NovoOkno.png) |
---|
Copyright: | 2018 Maximilian Hochmair |
---|
Note: | Soavtorji: Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten & Tanja Cufer;
Nasl. z nasl. zaslona;
Opis vira z dne 9. 1. 2019;
|
---|
Publication date in DiRROS: | 09.11.2020 |
---|
Views: | 1651 |
---|
Downloads: | 991 |
---|
Metadata: | ![Export as DC-RDF DC-RDF](teme/dirros/img/icon_dc_rdf.gif) |
---|
:
|
Copy citation |
---|
| | | Share: | ![Bookmark and Share](teme/dirros/img/addtoany.png) |
---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |